Pre study for MRI Linac: interfractional anatomical and dosimetry changes based on CBCT images for rectal cancer.

L. Calmels* and C. F. Behrens
Herlev Hospital, University of Copenhagen, Radiotherapy Research Unit, Herlev, Denmark
* Corresponding author: lucie.carole.anne.calmels@regionh.dk

Aim: Study anatomical changes and predict the dosimetric consequences for rectum cancer to evaluate the usefulness of magnetic resonance imaging (MRI) linear accelerator (Linac)

Methods:
- Rectal delineation on planning CT (pCT) and cone beam CT (CBCT)
- Deformable image registration (DIR) on pCT based on weekly CBCT
- Dose distribution recalculation
- Dose and volume evaluation: Clinical target volume (CTV), bladder, bowel

51 rectal cancer patients

Results: Rectum delineation
- Rectal volume: decrease for 32 patients, stable for 4 patients, increase for 4 patients (figure 1)
- Poor quality CBCT images: 10 patients excluded
- Sum of all rectum: larger than CTV Tumor but smaller than pCT Tumor (figure 2)

Results: DIR for CTV Tumor
- The CTV Tumor was well covered (figure 3).
- The mean CTV Tumor volume decreases of 13% between the pCT and the last fraction of treatment (figure 4)

Results: DIR for bowel and bladder
- The median volume of bladder is smaller on all deformed CB compared to pCT (figure 5).
- The bladder volume receiving more than 35 Gy is stable.
- For 9 patients, more than 20% of the bladder volume received more than 50 Gy during the treatment (figure 6).
- The bowel dose and volume are stable during the treatment.

Conclusions:
- DIR works for bone and target. Difficulties with artefact on CBCT images, bowel gas and large bladder volume differences between pCT and CBCT.
- Except bladder, all structures received similar dose at all treatment fractions.
- 10 patients are excluded because of the poor quality image of CBCT (gas in the bowel, big patient).

We assumed that MRI Linac can be used to delineate the rectum and/or the tumor more precisely, making it possible to reduce the PTV margin.

Figure 1: mean percentage rectal volume difference (%) during the treatment.
Figure 2: Axial, sagittal and coronal slice showing CTV Tumor (blue), CTV Tumor(delineated) on pCT (yellow) and total sum rectum created (brown) for one patient.
Figure 3: Boxplot of the minimum dose received by CTV Tumor during the treatment.
Figure 4: Boxplot of the CTV Tumor volume during the treatment.
Figure 5: Boxplot of the bladder volume during the treatment.
Figure 6: Boxplot of the volume of bladder receiving more than 50Gy during the treatment.